Exosens · EURONEXT:EXENS

Exosens — H1 2024 Earnings Presentation

37 slides from Exosens's earnings presentation, Sep 3, 2024

  1. Slide 1: H1 2024 Results

    H1 2024 Results September 3rd , 2024 © EXOSENS restricted & confidential

  2. Slide 2: Disclaimer

    DISCLAIMER Certain information included in this presentation are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding Exosens’ present and future busi

  3. Slide 3: Today's presenters

    Today’s presenters Jérôme Cerisier Quynh-Boi Demey Chief Executive Officer Chief Financial Officer © EXOSENS restricted & confidential 3

  4. Slide 4: I. Exosens introduction

    I. Exosens introduction © EXOSENS restricted & confidential

  5. Slide 5: We provide innovative technology for a safer world

    Our purpose We provide innovative amplification, detection and imaging technology components © EXOSENS restricted & confidential for a safer world 5

  6. Slide 6: We are a global leader in Amplification and Detection & Imaging

    We are a global leader in Amplification and Detection & Imaging LEADER Top 1-2 player Highly attractive IN NICHE in most of addressed markets €3.2bn TAM markets: Defense, Industrial GROWING (~71% market share in Light Amplification, (~8% CAGR 2023-27) MARKETS1 ~24% in core addressed detection market

  7. Slide 7: Exosens is focused on critical components driving end-user product performance

    Exosens is focused on critical components driving the performance of products for end-users Business unit Key products Light Electronic Defense Amplification Amplification Intensifier tubes Lifescience Detection Imaging Digital cameras Industrial Detection Imaging control Digital cameras © EXOSENS r

  8. Slide 8: What we want to achieve

    What we want to achieve Be a leading technology platform across the particle and light spectrum… …cross-fertilising fast-growing markets and high value technologies… …through innovation, global commercial reach and selective acquisitions… …with balanced revenue between Amplification and Detection &

  9. Slide 9: Key highlights of H1 2024

    Key highlights of H1 2024 Strong financial Revenues of €186.9m, +50% vs. H1 2023, and +35% organic growth growth Increasing Adjusted EBITDA of €56.1m (vs. €34.0m for H1 2023) margin EBITDA margin of 30.0% (+278bps vs. H1 2023) Decreasing leverage 1.3x total net debt / adjusted EBITDA as at June 30th

  10. Slide 10: II. Update on Exosens' key markets

    markets II. Update on Exosens’ key © EXOSENS restricted & confidential

  11. Slide 11: Key drivers of our markets

    Key drivers of our markets Amplification Detection & Imaging Industrial control: Intense conventional warfare in Ukraine • Increasing devices performance US protectionist measures Rise of tensions in • Better product quality control Iran and Lebanon Rise of China military strength and presence • Fas

  12. Slide 12: Focus on Night Vision

    Amplification Detection & Imaging Focus on Night Vision Significant spending increase in Europe supported by resurgence of international threats NV market remains robust Key tactical advantage of night operation ability for high density combat with sustainable growth Acquisition rates across segment

  13. Slide 13: Countries prioritize large scale night fighting capabilities

    Amplification Detection & Imaging Countries prioritize large scale night fighting capabilities following Ukraine war and high intensity conflict comeback • Ukraine war main lessons are that territorial claims tend to be resolved by man to man combat highlighting criticality of night fighting capabil

  14. Slide 14: NATO & Tier users still need to procure ~50% of needed NV devices

    Amplification Detection & Imaging NATO & Tier 1 users still need to procure ~50% of needed NV devices above our market view after 5 years, ensuring long-term growth of Exosens addressed market Core addressed market - USA excluded (€m) Growth relies on forecasted investment and increase of equipment

  15. Slide 15: Our D&I components serve markets with strong secular growth

    Amplification Detection & Imaging Our D&I components serve markets benefitting from strong secular growth Semiconductor Electrical Machine vision Gas detection Lifescience N uclear Defense Science inspection Power • Battery • C limate change inspection issue • Genomic and • D riven by IoT, • D riven

  16. Slide 16: III. H1 results

    III. H1 results © EXOSENS restricted & confidential

  17. Slide 17: Excellent H1 performance, driven by organic growth and margin expansion

    Excellent H1 performance, driven by organic growth and margin expansion H1 2023 H1 2024 Change % of % of In €m In €m sales sales Revenue 125.0 186.9 49.5% Gross margin1 56.6 45.3% 91.1 48.8% 61.0% Indirect costs (22.6) (18.0%) (35.0) (18.7%) 55.1% Adjusted EBITDA 34.0 27.2% 56.1 30.0% 64.9% Deprecia

  18. Slide 18: Continued growth momentum, revenues up 50%

    Continued growth momentum, revenues up 50% Revenue (in €m) Growth vs. FY guidance +35% organic Total Organic 50% 19.0 186.9 44.1 (1.2) 35% ~30% 125.0 High teens © EXOSENS restricted & confidential 1 H1 2023 Amplification D&I I/C elimination H1 2024 YoY growth FY 2024 YoY growth FY 2024 guidance guid

  19. Slide 19: Focus on segments

    Focus on segments Amplification Detection & Imaging Revenue: Gross margin (% margin): Revenue: Gross margin (% margin): 138.5 44.6% 47.1% 45.8% 51.1% 94.3 75.2 Q2 65.2 +18.8% 42.1 50.4 31.5 25.8 63.3 Q1 26.2 Q2 14.4 +8.3% 24.2 Q1 H1 2023 H1 2024 H1 2023 H1 2024 H1 2023 H1 2024 H1 2023 H1 2024 Strong

  20. Slide 20: Profitability increases significantly at group level and across both segments

    Profitability increases significantly at group level and across both segments In €m % margin Margin expansion drivers Gross margin: Total Amplification D&I 91.1 +350bps +247bps +527bps 56.6 25.8 14.4 45.3% 48.8% 44.6% 47.1% 45.8% 51.1% 65.2 42.1 0.0 H1 2023 0.1 H1 2024 H1 23 H1 24 H1 23 H1 24 H1 23

  21. Slide 21: Continued investment in R&D to remain at the edge of technology

    Continued investment in R&D to remain at the edge of technology R&D (€m) Comments Gross R&D as% of sales 8.0% 7.9% Increase of R&D spent by €3.5m of which +€1.6m from innovation projects (prior to Net R&D1 as % of sales 6.7% 6.3% proof of concept) and +€1.9m scope Increase of customer co-investments

  22. Slide 22: Capex optimization plan under way, now at 7% of sales

    Capex optimization plan under way, now at 7% of sales Capex excluding R&D capitalised (€m) Comments Start of normalisation of capex after % of sales 8.8% 7.0% investment for capacity done in 2022 and 2023 6.4% 3.9% Higher investment in Maintenance to optimise existing assets and support future margi

  23. Slide 23: Solid cash flow generation during H1 2024

    Solid cash flow generation during H1 2024 In €m H1 2023 H1 2024 Comments Adjusted EBITDA 34.0 56.1 Capitalised R&D (4.3) (4.6) Adjusted EBITDA post Cap. R&D 29.7 51.5 €23.6m FCF in the period, of which €22m organic and €1.6m from scope effect Change in WC (13.2) (7.7) Tax paid (3.0) (1.6) Other inco

  24. Slide 24: Our capital structure fully supports our growth strategy

    Our capital structure fully supports our growth strategy In €m 30-Jun-24 Comments Term loan 250.0 Borrowings details: Other bank debt 3.6 • Debt fully refinanced at IPO in June, with the current structure comprising IFRS 16 lease liabilities 9.9 of: ‒ €250m term loan, maturing in Total gross debt 26

  25. Slide 25: IV. Conclusion & outlook

    IV. Conclusion & outlook © EXOSENS restricted & confidential

  26. Slide 26: Significant growth, profitability and cash conversion improvement

    Significant growth, profitability and cash conversion improvement: fully on track to deliver our guidance Strong start of the year with a growth of 49.5% growth (+€61.9m), driven by: Acceleration of revenue growth • Strong organic growth of 35.0% with significant traction in group sales volume coupl

  27. Slide 27: Fully on track to deliver our guidance

    Fully on track to deliver our guidance FY 24E Mid-term (2027 target) • We expect to grow organically at high-single digit in 2023-27E, with • High teens organic growth above mid-single digit yearly growth in 2025-27E Revenue • Around 30% total growth including acquisitions • We expect a near doublin

  28. Slide 28: Key developments post H1 2024

    Key developments post H1 2024 2 synergistic acquisitions completed in August Ecovadis Silver Medal Closing: July 31st, 2024 Closing: September 1st, 2024 Silver Medal awarded on August 5th, 2024 Country: UK Country: Canada Placed Exosens in the top 15% worldwide 2023 sales1: GBP 11.0m 2023 sales2: CA

  29. Slide 29: Next period's key priorities / milestones

    Next period’s key priorities / milestones Amplification D&I M&A Execute increased capacity plan Detection: Increase design-in Start integration of Centronic and penetration of Tier 1 customers in LR Tech Continue development of Next Gen electron microscopy and product towards official commercial sem

  30. Slide 30: Q&A

    Q&A © EXOSENS restricted & confidential

  31. Slide 31: Appendix

    Appendix © EXOSENS restricted & confidential

  32. Slide 32: Income statement

    Income statement In €m H1 2023 H1 2024 Revenue 125.0 186.9 Purchases consumed (30.5) (45.6) Other purchases and external expenses (24.1) (33.9) Taxes (0.9) (1.2) Personnel expenses (38.9) (55.5) Other operating income / (expenses) 1.5 (0.6) Depreciation and amortisation (11.5) (15.5) o/w PPA amortis

  33. Slide 33: Cash flow statement

    Cash flow statement In €m H1 2023 H1 2024 Profit / (loss) 8.3 2.9 Net financial result 9.5 25.7 Corporate income taxes 1.4 2.1 Depreciation and amortisation 11.5 15.5 Other income and expenses 1.3 2.9 Taxes paid (3.0) (1.6) Change in net working capital (13.2) (7.7) Cash flow from operating activiti

  34. Slide 34: Balance sheet – assets

    Balance sheet – assets In €m 31-Dec-2023 H1 2024 Goodwill 174.3 174.3 Intangible assets 202.4 198.8 Tangible assets 72.1 79.4 Right-of-use of leases 10.8 9.9 Investment in associates 3.4 3.4 Financial assets and other long-term investments 0.7 1.2 Deferred tax assets 0.0 1.5 Long-term assets 463.7 4

  35. Slide 35: Balance sheet – equity and liabilities

    Balance sheet – equity and liabilities In €m 31-Dec-2023 H1 2024 Share capital 1.9 21.6 Additional paid-in capital 188.1 340.6 Retained earnings 14.1 19.8 Total equity 204.1 382.0 Long-term financial debt 300.8 249.0 Long-term lease liabilities 7.7 7.6 Pension liabilities 7.6 7.7 Provisions and othe

  36. Slide 36: Operating profit bridge

    Operating profit bridge In €m H1 2023 H1 2024 Comments Operating Profit 19.2 30.7 Depreciation, amortisation and impairment - net 11.1 15.9 1 Costs mainly attributable to consultancy & advisory expenses for M&A 1 2 Other income and expenses 1.4 3.9 2 Costs incurred in the context of the IPO EBITDA 3

  37. Slide 37: Financial glossary

    FINANCIAL GLOSSARY Organic growth is the growth in revenue achieved by the Group on a like-for-like basis, which corresponds to revenue achieved during period “n” by all the companies included in the Group’s scope of consolidation at the end of period “n1” (excluding any contribution from companies

Exosens — H1 2024 Earnings Presentation on 6ix